Clinical Trials
7 trialsNCT07557914 2026-06-03
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT05507632 2026-06-01
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Active not recruiting
NCT07584018 2026-05-13
The DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04418401 2026-02-17
CISLD-8
Zhejiang University
Phase 1 Completed
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT07180459 2025-09-18
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
The First Affiliated Hospital of Zhengzhou University
Not yet recruiting
NCT07157306 2025-09-05
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting